$CRBP I did some DD today, the Phase 2 Lebanusum DM trial had a P =0.001 result (Statistical significance requires <0.05), and 20 percent Adverse effect. This is good. The other Scolosis whatever trial that failed in 2020 had a 63% Adverse effect and an average 0.11 p value in Phase 2. The subjects were monitored for 140+weeks, thats enough time to know if something would go wrong. I am positive about Phase 3. My only concern is why was the timeline shifted upwards, could COVID have interfered with the trial or patients?